Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will conduct a conference call on October 28, 2021, at 8:00 a.m. ET to discuss financial results for the quarter ending September 30, 2021, alongside recent business achievements. Interested parties can join via dial-in or a live webcast available on their corporate website. Aldeyra is focused on developing immune-modulating therapies for ocular and systemic diseases, with key products in clinical trials targeting inflammation-related conditions. For further details, visit their website.

Positive

• Aldeyra is conducting Phase 3 trials for lead product reproxalap, targeting dry eye disease and allergic conjunctivitis.
• The clinical pipeline includes ADX-2191, in Phase 3 testing for preventing proliferative vitreoretinopathy.

Negative

• None.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, October 28, 2021 to report financial results for the quarter ended September 30, 2021 and discuss recent business highlights.

The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 8891298. A live webcast of the conference call will also be available on the Investors & Media page of the company’s corporate website at https://ir.aldeyra.com.

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005142/en/

Corporate Contact:

Joshua Reed

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

jreed@aldeyra.com

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

What is Aldeyra Therapeutics' financial quarter ending date?

The financial quarter for Aldeyra Therapeutics ended on September 30, 2021.

When will Aldeyra report its financial results?

Aldeyra will report its financial results on October 28, 2021.

How can I join the Aldeyra Therapeutics conference call?

You can join the conference call by dialing (866) 211-4098 for domestic callers or (647) 689-6613 for international callers.

What are the main products being developed by Aldeyra Therapeutics?

Aldeyra is developing reproxalap and ADX-629, targeting inflammation-related eye and systemic diseases.